Outlook Therapeutics Presents NORSE TWO Phase 3 Pivotal Safety and Efficacy Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at the Retina Subspecialty Day, American Academy of Ophthalmology (AAO) 2021 Annual Conference

Daniel Sontupe
Market Access

Joey Cohen
Medication Adherence

Matt Turner
Patient Affordability

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Matthew Durham
Omnidynamic Marketing

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

Liz Kane
Impactful Strategy